We recently published a list of Jim Cramer Says Trump’s Tariff Strategy Is Working & Discusses These 11 Stocks. In this ...
Johnson & Johnson's long-term prospects are promising due to strong drug pipeline developments and significant R&D ...
Johnson & Johnson (NYSE:JNJ – Get Free Report) has received a consensus rating of “Moderate Buy” from the eighteen research ...
Zacks Investment Research on MSN6d
Here's How to Play JNJ Stock as it Announces $55B US Investment PlanJ&J JNJ announced plans to invest more than $55 billion over the next four years to expand its manufacturing footprint in the ...
Johnson & Johnson's spin-off of Kenvue has created two resilient defensive stocks in the healthcare sector, ideal for accumulation during market volatility. Despite being off their highs, both JNJ and ...
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The latest trading day saw Johnson & Johnson (JNJ) settling at $163.29, representing a -0.21% change from its previous close.
American pharmaceutical giant Johnson & Johnson (JNJ) is boosting its U.S. investments by 25% to more than $55 billion over ...
JOHNSON & JOHNSON (JNJ) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 81% based on the firm’s underlying fundamentals and the stock’s ...
Investing in stocks comes with risks. There's no way around that fact. However, some stocks can be less risky than others during certain market conditions. Three Motley Fool contr ...
JOHNSON & JOHNSON (JNJ) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 81% based on the firm’s underlying fundamentals and the stock’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback